Related Experiment Video
Updated: Jun 22, 2025
04:49
Technique for Intranasal Administration of α-Synuclein Aggregates
Published on: November 8, 2024
433
Developing disease-modifying interventions in idiopathic REM sleep behavior disorder and early synucleinopathy
Dario Arnaldi1, Alex Iranzo2, Flavio Nobili3
1Department of Neuroscience (DINOGMI), University of Genoa, Genoa, Italy; Neurofisiopatologia, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Parkinsonism & Related Disorders
|June 29, 2024
Summary
Targeting REM sleep behavior disorder (RBD) offers a promising strategy for early intervention in alpha-synucleinopathies. This approach leverages the disorder's prodromal phase to develop effective disease-modifying therapies.
Area of Science:
- Neurology
- Sleep Medicine
- Neurodegenerative Diseases
Background:
- Alpha-synucleinopathies cause significant disability with current treatments focused on symptom management.
- Disease-modifying therapies have shown limited success in established disease stages.
- A long prodromal phase in alpha-synucleinopathies presents a critical window for therapeutic intervention.
Purpose of the Study:
- To discuss the rationale for targeting idiopathic/isolated REM sleep behavior disorder (RBD) in disease-modifying trials for alpha-synucleinopathies.
- To outline potential study designs for such trials.
- To summarize potential therapeutic targets for alpha-synucleinopathies.
Main Methods:
- Identifying polysomnography-confirmed REM sleep behavior disorder (RBD) as the most reliable prodromal marker.
- Discussing strategies for patient stratification and selection based on biomarkers.
- Reviewing suitable endpoints for assessing disease modification.
Main Results:
- Polysomnography-confirmed REM sleep behavior disorder (RBD) is a key indicator for identifying individuals in the prodromal stage of alpha-synucleinopathy.
- Targeting idiopathic/isolated RBD in clinical trials is a viable strategy for disease modification.
- Specific biomarkers and endpoints are crucial for trial success.
Conclusions:
- Intervention during the prodromal phase of alpha-synucleinopathies, particularly in individuals with RBD, holds significant therapeutic potential.
- Careful study design, patient stratification, and appropriate endpoint selection are essential for developing effective disease-modifying therapies.
- Further research into therapeutic targets is warranted.
Related Concept Videos
01:15REM Sleep Behavior Disorder
179
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
RBD is significantly associated with...
179
01:15Parkinson's Disease: Overview
523
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
523
01:24Parkinson's Disease: Treatment
254
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
254
01:07Narcolepsy
101
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
101
01:37Neural Regulation
39.3K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.3K
01:22Alzheimer's Disease: Treatment
178
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
178